The US Angiogenesis Foundation’s white paper “Advocating for Improved Treatment and Outcomes for Wet Age-Related Macular Degeneration” was the result of the Australian Wet Age-Related Macular Degeneration Coalition Expert Summit in July 2012. The summit was convened by the Angiogenesis Foundation and Macular Disease Foundation Australia, marking a significant step forward in the fight against this eye disease.
Ophthalmologists and other leading eye healthcare stakeholders from across Australia gathered in Sydney to address barriers to timely and optimal care for Australian patients with vision loss due to wet age-related macular degeneration.
Speaking of the whitepaper, Macular Disease Foundation Australia CEO, Julie Heraghty said, “The document summarises key discussions from the summit and makes specific recommendations aimed at informing national health services, the clinical and research community, and patient advocates. We hope this white paper will play an important role in influencing the management of macular degeneration in the future. The treatment window for wet age-related macular degeneration is relatively short, so any delay in treatment can mean the difference between retaining vision and going blind.”
The number of Australians living with age-related macular degeneration is expected to grow to over 1.7 million by 2030 in the absence of effective prevention and treatment measures.
The white paper provides an extensive analysis of the issues and needs for age-related macular degeneration patients in Australia’s healthcare system.
You can download it here.